{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:14:11Z","timestamp":1788448451679,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82002465"],"award-info":[{"award-number":["82002465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172711"],"award-info":[{"award-number":["82172711"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515011786"],"award-info":[{"award-number":["2019A1515011786"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03796-1","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T09:05:12Z","timestamp":1725527112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration"],"prefix":"10.1007","volume":"73","author":[{"given":"Yunxin","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuqiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaozhen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peidong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"3796_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17:557\u2013588. https:\/\/doi.org\/10.1038\/s41575-020-0310-z","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3796_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX (2021) Biliary tract cancer. Lancet 397:428\u2013444. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7","journal-title":"Lancet"},{"key":"3796_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 73:198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759","journal-title":"CA Cancer J Clin"},{"key":"3796_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"3796_CR5","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol Off J Eur Soc Med Oncol 30:1950\u20131958. https:\/\/doi.org\/10.1093\/annonc\/mdz402","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"3796_CR6","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/annonc\/mdz058","volume":"30","author":"ST Kim","year":"2019","unstructured":"Kim ST, Kang JH, Lee J et al (2019) Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann oncol Off J Eur Soc Med Oncol 30:788\u2013795. https:\/\/doi.org\/10.1093\/annonc\/mdz058","journal-title":"Ann oncol Off J Eur Soc Med Oncol"},{"key":"3796_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","volume":"123","author":"A Sharma","year":"2019","unstructured":"Sharma A, Kalyan Mohanti B, Pal Chaudhary S et al (2019) Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: results of a phase III randomised controlled trial. Eur J Cancer 123:162\u2013170. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.004","journal-title":"Eur J Cancer"},{"key":"3796_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang DR, Wu XL, Sun YL (2022) Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther 7:331. https:\/\/doi.org\/10.1038\/s41392-022-01136-2","journal-title":"Signal Transduct Target Ther"},{"key":"3796_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","volume":"6","author":"RD Kim","year":"2020","unstructured":"Kim RD, Chung V, Alese OB et al (2020) A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 6:888\u2013894. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0930","journal-title":"JAMA Oncol"},{"key":"3796_CR10","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M et al (2020) Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 147:2190\u20132198. https:\/\/doi.org\/10.1002\/ijc.33013","journal-title":"Int J Cancer"},{"key":"3796_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno M, Ikeda M, Morizane C et al (2019) Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol 4:611\u2013621. https:\/\/doi.org\/10.1016\/S2468-1253(19)30086-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3796_CR12","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-22-1152","volume":"28","author":"NJ Chiang","year":"2022","unstructured":"Chiang NJ, Tan KT, Bai LY et al (2022) Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract cancer: a phase II T1219 study. Clin Cancer Res Off J Am Ass Cancer Res 28:4248\u20134257. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1152","journal-title":"Clin Cancer Res Off J Am Ass Cancer Res"},{"key":"3796_CR13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s41467-023-37030-w","volume":"14","author":"TM Zeng","year":"2023","unstructured":"Zeng TM, Yang G, Lou C et al (2023) Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nat Commun 14:1340. https:\/\/doi.org\/10.1038\/s41467-023-37030-w","journal-title":"Nat Commun"},{"key":"3796_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2022.100255","volume":"3","author":"W Li","year":"2022","unstructured":"Li W, Wang Y, Yu Y et al (2022) Toripalimab in advanced biliary tract cancer. Innovation 3:100255. https:\/\/doi.org\/10.1016\/j.xinn.2022.100255","journal-title":"Innovation"},{"key":"3796_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001240","author":"X Chen","year":"2020","unstructured":"Chen X, Wu X, Wu H et al (2020) Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001240","journal-title":"J Immunother Cancer"},{"key":"3796_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet"},{"key":"3796_CR17","doi-asserted-by":"crossref","unstructured":"Oh DY, He AR, Qin S, et al (2022) A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. NEJM Evidence. 1","DOI":"10.1200\/JCO.2022.40.4_suppl.378"},{"key":"3796_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00003","volume":"6","author":"SS Liddell","year":"2022","unstructured":"Liddell SS, Chakrabarti S, Wintheiser GA et al (2022) Tumor mutational burden is a potential predictive biomarker for response to immune checkpoint inhibitors in patients with advanced biliary tract cancer. JCO Precis Oncol 6:e2200003. https:\/\/doi.org\/10.1200\/PO.22.00003","journal-title":"JCO Precis Oncol"},{"key":"3796_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003214","author":"X Chen","year":"2021","unstructured":"Chen X, Wang D, Liu J et al (2021) Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003214","journal-title":"J Immunother Cancer"},{"key":"3796_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100883","volume":"65","author":"LF Ye","year":"2022","unstructured":"Ye LF, Huang ZY, Chen XX et al (2022) Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA. Drug Resist Updates Rev Comm Antimicrob Anticancer Chemother 65:100883. https:\/\/doi.org\/10.1016\/j.drup.2022.100883","journal-title":"Drug Resist Updates Rev Comm Antimicrob Anticancer Chemother"},{"key":"3796_CR21","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S et al (2023) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. Liver Int Off J Int Ass Study Liver 43:1803\u20131812. https:\/\/doi.org\/10.1111\/liv.15641","journal-title":"Liver Int Off J Int Ass Study Liver"},{"key":"3796_CR22","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.annonc.2023.09.1391","volume":"34","author":"S Qin","year":"2023","unstructured":"Qin S, Cai JQ, Li E et al (2023) 98P Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study. Ann Oncol 34:S216\u2013S217. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1391","journal-title":"Ann Oncol"},{"key":"3796_CR23","doi-asserted-by":"publisher","first-page":"S220","DOI":"10.1016\/j.annonc.2023.09.1395","volume":"34","author":"AR He","year":"2023","unstructured":"He AR, Bouattour M, Gupta VG et al (2023) 102P Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study. Ann Oncol 34:S220. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1395","journal-title":"Ann Oncol"},{"key":"3796_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00262-022-03328-9","volume":"72","author":"A Szeles","year":"2023","unstructured":"Szeles A, Fazekas T, Vancsa S et al (2023) Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Cancer Immunol Immunother CII 72:1061\u20131073. https:\/\/doi.org\/10.1007\/s00262-022-03328-9","journal-title":"Cancer Immunol Immunother CII"},{"key":"3796_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1245\/s10434-018-07112-x","volume":"26","author":"T Shigemori","year":"2019","unstructured":"Shigemori T, Toiyama Y, Okugawa Y et al (2019) Soluble PD-L1 expression in circulation as a predictive marker for recurrence and prognosis in gastric cancer: direct comparison of the clinical burden between tissue and serum PD-L1 expression. Ann Surg Oncol 26:876\u2013883. https:\/\/doi.org\/10.1245\/s10434-018-07112-x","journal-title":"Ann Surg Oncol"},{"key":"3796_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212978","volume":"14","author":"T Tominaga","year":"2019","unstructured":"Tominaga T, Akiyoshi T, Yamamoto N, Taguchi S, Mori S, Nagasaki T, Fukunaga Y, Ueno M (2019) Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. PLoS ONE 14:e0212978. https:\/\/doi.org\/10.1371\/journal.pone.0212978","journal-title":"PLoS ONE"},{"key":"3796_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.imlet.2011.11.001","volume":"142","author":"X Frigola","year":"2012","unstructured":"Frigola X, Inman BA, Krco CJ, Liu X, Harrington SM, Bulur PA, Dietz AB, Dong H, Kwon ED (2012) Soluble B7\u2013H1: differences in production between dendritic cells and T cells. Immunol Lett 142:78\u201382. https:\/\/doi.org\/10.1016\/j.imlet.2011.11.001","journal-title":"Immunol Lett"},{"key":"3796_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh SA, Wu DC, Cheung J et al (2020) PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nature cancer 1:681\u2013691. https:\/\/doi.org\/10.1038\/s43018-020-0075-x","journal-title":"Nature cancer"},{"key":"3796_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/gutjnl-2016-312078","volume":"66","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Velez-Delgado A, Mathew E et al (2017) Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut 66:124\u2013136. https:\/\/doi.org\/10.1136\/gutjnl-2016-312078","journal-title":"Gut"},{"key":"3796_CR30","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1158\/1078-0432.CCR-22-1123","volume":"28","author":"AN Ruggieri","year":"2022","unstructured":"Ruggieri AN, Yarchoan M, Goyal S et al (2022) Combined MEK\/PD-L1 inhibition alters peripheral cytokines and lymphocyte populations correlating with improved clinical outcomes in advanced biliary tract cancer. Clin Cancer Res 28:4336\u20134345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1123","journal-title":"Clin Cancer Res"},{"key":"3796_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114884","volume":"245","author":"J Wen","year":"2023","unstructured":"Wen J, Wang S, Guo R, Liu D (2023) CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment. Eur J Med Chem 245:114884. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114884","journal-title":"Eur J Med Chem"},{"key":"3796_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D (2017) Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 5:53. https:\/\/doi.org\/10.1186\/s40425-017-0257-y","journal-title":"J Immunother Cancer"},{"key":"3796_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y (2021) Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther 6:127. https:\/\/doi.org\/10.1038\/s41392-021-00506-6","journal-title":"Signal Transduct Target Ther"},{"key":"3796_CR34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/hep.32387","volume":"76","author":"C Luo","year":"2022","unstructured":"Luo C, Xin H, Zhou Z et al (2022) Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression. Hepatology 76:982\u2013999. https:\/\/doi.org\/10.1002\/hep.32387","journal-title":"Hepatology"},{"key":"3796_CR35","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","volume":"72","author":"MA Martin-Serrano","year":"2023","unstructured":"Martin-Serrano MA, Kepecs B, Torres-Martin M et al (2023) Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 72:736\u2013748. https:\/\/doi.org\/10.1136\/gutjnl-2021-326514","journal-title":"Gut"},{"key":"3796_CR36","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","volume":"68","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Yang J, Xu D et al (2019) Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut 68:1653\u20131666. https:\/\/doi.org\/10.1136\/gutjnl-2019-318419","journal-title":"Gut"},{"key":"3796_CR37","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA et al (2014) CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Can Res 74:5057\u20135069. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3723","journal-title":"Can Res"},{"key":"3796_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/10799893.2017.1328441","volume":"37","author":"M Thomas","year":"2017","unstructured":"Thomas M, Snead D, Mitchell D (2017) An investigation into the potential role of brain angiogenesis inhibitor protein 3 (BAI3) in the tumorigenesis of small-cell carcinoma: a review of the surrounding literature. J Recept Signal Transduct Res 37:325\u2013334. https:\/\/doi.org\/10.1080\/10799893.2017.1328441","journal-title":"J Recept Signal Transduct Res"},{"key":"3796_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12920-016-0239-9","volume":"10","author":"A Paziewska","year":"2017","unstructured":"Paziewska A, Habior A, Rogowska A et al (2017) A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. BMC Med Genomics 10:2. https:\/\/doi.org\/10.1186\/s12920-016-0239-9","journal-title":"BMC Med Genomics"},{"key":"3796_CR40","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s12328-022-01649-x","volume":"15","author":"Y Masaki","year":"2022","unstructured":"Masaki Y, Akutsu N, Adachi Y et al (2022) Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma. Clin J Gastroenterol 15:809\u2013817. https:\/\/doi.org\/10.1007\/s12328-022-01649-x","journal-title":"Clin J Gastroenterol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03796-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T16:03:52Z","timestamp":1729785832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03796-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["3796"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03796-1","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"7 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and was approved by the Ethical Committee of Sun Yat-sen University Cancer Center. Written consent was obtained from all participants during their hospitalization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"220"}}